New Haven, CT – September 1, 2020 - Today, Bonde Innovations, LLC announced that the company has been awarded a Phase 1 Small Business Innovation Research (SBIR) grant in the amount of $555,358 from the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH)(link is external) for continued development of CoRISMA, a transcatheter therapeutic device designed to treat advanced Heart Failure (HF), including patients with reduced and preserved ejection fraction.

HF is a global pandemic affecting 23 million worldwide and 6 million in the US, with 650,000 new cases diagnosed in the US each year. It is a relentless disease that progresses to end stages with very poor prognosis, in which heart transplantation or left ventricular assist device (LVAD) therapy becomes the only available treatment option. A significant rise in the LVAD use for end-stage HF is due to critical donor shortage. However, high costs, invasive implantation techniques, and frequent and severe complications limits its potential.

Mike Theran, the CEO of Bonde Innovations(link is external), said, “We believe CoRISMA can dramatically improve the treatment options for heart failure patients around the world.  This NIH grant provides solid validation and allows us to accelerate our development efforts.”

CoRISMA is a fully implanted, catheter delivered, wirelessly powered novel cardiac device designed to provide circulation assistance for advanced heart failure patients.

About Bonde Innovations:

Based in New Haven, Bonde Innovations is a Yale University spinout based on years of research at the Bonde Artificial Heart Lab, led by Pramod Bonde, MD, a cardiac surgeon at Yale New Haven Hospital and Associate Professor of Surgery at Yale School of Medicine.

About the Yale Venture:

Since its founding in 1982, the Yale Venture (OCR) has built a significant portfolio of inventions and patents and has grown into an engine of regional economic development. Its mission is to facilitate the translation of research from Yale’s labs into products and services that benefit society. OCR is recognized as a leading force for catalyzing economic growth by identifying, counseling and nurturing early-stage technologies and guiding the transition into robust companies. More information is available at https://ocr.yale.edu/. 

MEDIA CONTACT:

Michelle McQueen

Yale University, Office of Cooperative Research

michelle.mcqueen@yale.edu(link sends e-mail)

+1 917-370-6016